NASDAQ:XBIOW Xenetic Biosciences (XBIOW) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free XBIOW Stock Alerts $6.54 -1.46 (-18.25%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$6.54▼$6.5450-Day Range$6.54▼$14.7052-Week Range$0.94▼$23.16Volume102 shsAverage Volume679 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Xenetic Biosciences alerts: Email Address Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About Xenetic Biosciences Stock (NASDAQ:XBIOW)Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.Read More XBIOW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIOW Stock News HeadlinesMay 18 at 4:06 AM | americanbankingnews.comXenetic Biosciences (NASDAQ:XBIOW) Shares Down 18.3% May 12, 2024 | finance.yahoo.comXenetic Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 10, 2024 | finance.yahoo.comXenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | investorplace.comXBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q1 2024March 22, 2024 | msn.comXBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023March 22, 2024 | finance.yahoo.comXenetic Biosciences, Inc. Reports Full Year 2023 Financial ResultsJanuary 17, 2024 | finance.yahoo.comXenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology PlatformNovember 10, 2023 | msn.comXenetic Biosciences reports Q3 resultsNovember 10, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Reports Third Quarter 2023 Financial ResultsSeptember 27, 2023 | investing.comXENX Historical DataSeptember 1, 2023 | finance.yahoo.comXenetic Biosciences, Inc. (XBIOW)August 11, 2023 | msn.comXenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue EstimatesJuly 12, 2023 | marketwatch.comXenetic Biosciences Shares Down 15% After Presentation, Tuesday IncreaseJuly 5, 2023 | finance.yahoo.comXenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight SeriesJune 12, 2023 | ca.finance.yahoo.comXBIOW - Xenetic Biosciences, Inc.See More Headlines Receive XBIOW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:XBIOW CUSIPN/A CIK1534525 Webwww.xeneticbio.com Phone17817787720FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.54 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Jeffrey F. Eisenberg Esq. (Age 58)CEO, President & Director Comp: $533.95kMr. James F. Parslow (Age 59)CFO, COO & Corporate Secretary Comp: $424.55kDr. Curtis A. Lockshin (Age 64)Chief Scientific Officer Comp: $420.93kKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors XBIOW Stock Analysis - Frequently Asked Questions How have XBIOW shares performed in 2024? Xenetic Biosciences' stock was trading at $4.00 on January 1st, 2024. Since then, XBIOW shares have increased by 63.5% and is now trading at $6.54. View the best growth stocks for 2024 here. How do I buy shares of Xenetic Biosciences? Shares of XBIOW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XBIOW) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
